Deals Of The Week: Johnson & Johnson/Pharmacyclics, AstraZeneca/Guangdong BeiKang, AstraZeneca/Medical Research Council
Executive Summary
As more and more biopharmaceutical companies jump on the biosimilars train, the complexities of this emerging business area are becoming clear.
You may also be interested in...
Biogen Tests Biosimilars Waters In Joint Venture With Samsung
A joint venture with Korean conglomerate Samsung will be limited to making generic versions of non-Biogen products, although Samsung separately is working on a biosimilar of rituximab.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.